EP300 and posterior cortical atrophy: Notably, a Phase I/IIa clinical trial (ClinicalTrials.gov Identifier: NCT03568656) was initiated for CBP/p300 BD inhibitor CCS1477 for treatment of metastatic PCa [94,199].